HUTCHMED (China) (HMDCF) Non-Current Assets (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Non-Current Assets came in at $183.0 million in Q2 2026, up 178.87% year-over-year from $65.6 million in Q2 2025, and up 176.83% quarter-over-quarter from $66.1 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Non-Current Assets (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Non-Current Assets for 12 consecutive years, with $183.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Assets rose 178.87% year-over-year to $183.0 million in Q2 2026; TTM through Jun 2026 was $763.9 million, a 1064.01% increase from a year earlier, with the FY2025 full-year figure at $66.1 million, down 2.15% from the prior year.
- Non-Current Assets was $183.0 million for Q2 2026 at HUTCHMED (China), up from $66.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $207.0 million in Q2 2023 and troughed at $65.6 million in Q2 2025.
- A 5-year average of $99.7 million and a median of $73.9 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets tumbled 66.52% in 2024 and soared 178.87% in 2026, its largest moves.
- Over 5 years, Non-Current Assets stood at $80.1 million in 2022, then slipped by 7.65% to $73.9 million in 2023, then retreated by 8.63% to $67.6 million in 2024, then decreased by 2.15% to $66.1 million in 2025, then soared by 176.83% to $183.0 million in 2026.
- The last three Non-Current Assets figures came in at $183.0 million (Q2 2026), $66.1 million (Q4 2025), and $65.6 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | 564.41 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 183.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 183.02 Mn |
| Dec 31, 2025 | 66.11 Mn |
| Jun 30, 2025 | 65.63 Mn |
| Dec 31, 2024 | 67.56 Mn |
| Jun 30, 2024 | 69.31 Mn |
| Dec 31, 2023 | 73.94 Mn |
| Jun 30, 2023 | 207.01 Mn |
| Dec 31, 2022 | 80.06 Mn |
| Jun 30, 2022 | 84.97 Mn |
| Dec 31, 2021 | 91.61 Mn |
| Jun 30, 2021 | 93.36 Mn |
| Mar 31, 2021 | 196.89 Mn |
| Dec 31, 2020 | 95.73 Mn |
| Jun 30, 2020 | 91.43 Mn |
| Dec 31, 2019 | 95.10 Mn |
| Sep 30, 2019 | 177.01 Mn |
| Jun 30, 2019 | 185.72 Mn |
| Mar 31, 2019 | 189.30 Mn |
| Dec 31, 2018 | 100.35 Mn |
| Jun 30, 2018 | 183.27 Mn |